FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387207516> ?p ?o ?g. }

• W4387207516 endingPage "S124" @default.
• W4387207516 startingPage "S124" @default.
• W4387207516 abstract "Factors contributing to brachial plexopathy (BPP) in the re-irradiation setting need further assessment. Preliminary work revealed that higher the doses and the use of concurrent cisplatin were associated with higher risk of BPP. Here, we expand our cohort and increase our follow-up duration, given the late nature of BPP development.Sixty-two BP sites with 41 patients (pts), treated between 2015 and 2020 for recurrent H&N cancer, were assessed. Contours and plans were reviewed via a prospective multidisciplinary chart rounds prior to treatment delivery and re-verified by two authors prior to this analysis. Kaplan-Meier and logistic regression were used to test the correlation between variables and outcomes. ROC was used to evaluate the cutoff values. Common terminology criteria of adverse events were used to define BPP.The median age of pts was 63 (29-78) and 65% were males. Median prescription dose was 70 Gy (60-70) for the 1st course and 66 Gy (44-70) for the 2nd course. 13% received intraoperative radiotherapy (IORT) during salvage treatment ranging from 10-15 Gy. 30% of pts in the 1st course and 80% in the 2nd course of pts had surgery. Concurrent chemotherapy was delivered to 71% of pts in the 1st course (Cisplatin 34%, Cetuximab 22%, Carboplatin +/- Paclitaxel 15%) and 76% in the 2nd course (Carboplatin/Paclitaxel 41%, Cisplatin 19%, Cetuximab 12%, Nivolumab 4%). The median interval between courses was 26.5 months (8-221). The median cumulative Dmax (0.03cc) and mean dose to the BP were 96.5 Gy (51-144) and 61.5 Gy (15-110), respectively. The median V60, V70, V80, V90, and V100 were 3.6cc (0.03-10.4), 2.4cc (0-9.9), 1.3cc (0-9.3), 0.6cc (0-8.4), and 0.0015cc (0-7.2), respectively. The median follow-up after the completion of the 2nd RT course was 19 months (1.4-71.5). The 1-yr incidence of BPP was 17%, with a median time to onset of 8.9 months (1-16.6). Factors associated with development of BPP were cumulative Dmax > 100 Gy (HR 1.06, [CI 1.014-1.1], p = 0.009), cumulative mean dose >70 Gy (HR 1.05, [CI 1.01-1.09], p = 0.03), V80 > 1.6cc (HR 1.2. [CI 0.99- 1.52], p = 0.06), V90 > 1cc (HR 1.3, [CI 1.013-1.58], p = 0.038), V100 > 0.3cc (HR 1.33, [1.044-1.69], p = 0.021) and the usage of concurrent cisplatin during the 2nd course (HR 8.9, [CI 2.36-33.75], p = 0.001). Other factors including gender, age, surgery, treatment interval between the two courses, IORT, V60, and V70 were not associated with increased risk of BPP. The incidence of grade 1, grade 2, and grade 3 BPP were 9.6%, 3% and 2.4%, respectively. The 1-yr OS was 70% and LC was 60%.At a median follow up of 19 months, the 1-yr incidence of grade 2 and 3 BPP was approximately 5%. Cisplatin during the 2nd course, cumulative metrics of Dmax 100 Gy, mean 70 Gy, V80 1.6cc, V90 1cc and V100 0.3cc were associated with development of BPP. Prospective study, longer follow up, and higher numbers are warranted. To our knowledge, this represents the largest cohort and longest follow up yet reported for BPP in the re-irradiation setting." @default.
• W4387207516 created "2023-09-30" @default.
• W4387207516 creator A5002998777 @default.
• W4387207516 creator A5009574782 @default.
• W4387207516 creator A5024756972 @default.
• W4387207516 creator A5030550568 @default.
• W4387207516 creator A5036139080 @default.
• W4387207516 creator A5059128200 @default.
• W4387207516 creator A5059965795 @default.
• W4387207516 creator A5066067745 @default.
• W4387207516 creator A5066127518 @default.
• W4387207516 creator A5067182017 @default.
• W4387207516 creator A5071419020 @default.
• W4387207516 creator A5092972794 @default.
• W4387207516 date "2023-10-01" @default.
• W4387207516 modified "2023-10-17" @default.
• W4387207516 title "Brachial Plexus Tolerance to Standard Fractionation Re-Irradiation: The Ohio State University Experience" @default.
• W4387207516 doi "https://doi.org/10.1016/j.ijrobp.2023.06.465" @default.
• W4387207516 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37784320" @default.
• W4387207516 hasPublicationYear "2023" @default.
• W4387207516 type Work @default.
• W4387207516 citedByCount "0" @default.
• W4387207516 crossrefType "journal-article" @default.
• W4387207516 hasAuthorship W4387207516A5002998777 @default.
• W4387207516 hasAuthorship W4387207516A5009574782 @default.
• W4387207516 hasAuthorship W4387207516A5024756972 @default.
• W4387207516 hasAuthorship W4387207516A5030550568 @default.
• W4387207516 hasAuthorship W4387207516A5036139080 @default.
• W4387207516 hasAuthorship W4387207516A5059128200 @default.
• W4387207516 hasAuthorship W4387207516A5059965795 @default.
• W4387207516 hasAuthorship W4387207516A5066067745 @default.
• W4387207516 hasAuthorship W4387207516A5066127518 @default.
• W4387207516 hasAuthorship W4387207516A5067182017 @default.
• W4387207516 hasAuthorship W4387207516A5071419020 @default.
• W4387207516 hasAuthorship W4387207516A5092972794 @default.
• W4387207516 hasConcept C126322002 @default.
• W4387207516 hasConcept C141071460 @default.
• W4387207516 hasConcept C2776694085 @default.
• W4387207516 hasConcept C2777793932 @default.
• W4387207516 hasConcept C2778239845 @default.
• W4387207516 hasConcept C2781451048 @default.
• W4387207516 hasConcept C2989005 @default.
• W4387207516 hasConcept C509974204 @default.
• W4387207516 hasConcept C71924100 @default.
• W4387207516 hasConceptScore W4387207516C126322002 @default.
• W4387207516 hasConceptScore W4387207516C141071460 @default.
• W4387207516 hasConceptScore W4387207516C2776694085 @default.
• W4387207516 hasConceptScore W4387207516C2777793932 @default.
• W4387207516 hasConceptScore W4387207516C2778239845 @default.
• W4387207516 hasConceptScore W4387207516C2781451048 @default.
• W4387207516 hasConceptScore W4387207516C2989005 @default.
• W4387207516 hasConceptScore W4387207516C509974204 @default.
• W4387207516 hasConceptScore W4387207516C71924100 @default.
• W4387207516 hasIssue "2" @default.
• W4387207516 hasLocation W43872075161 @default.
• W4387207516 hasLocation W43872075162 @default.
• W4387207516 hasOpenAccess W4387207516 @default.
• W4387207516 hasPrimaryLocation W43872075161 @default.
• W4387207516 hasRelatedWork W151172257 @default.
• W4387207516 hasRelatedWork W1984775533 @default.
• W4387207516 hasRelatedWork W2048005101 @default.
• W4387207516 hasRelatedWork W2085363994 @default.
• W4387207516 hasRelatedWork W2091003848 @default.
• W4387207516 hasRelatedWork W2151031435 @default.
• W4387207516 hasRelatedWork W2332602327 @default.
• W4387207516 hasRelatedWork W2380099415 @default.
• W4387207516 hasRelatedWork W2510670462 @default.
• W4387207516 hasRelatedWork W3013194840 @default.
• W4387207516 hasVolume "117" @default.
• W4387207516 isParatext "false" @default.
• W4387207516 isRetracted "false" @default.
• W4387207516 workType "article" @default.